Hyperphosphatemia

Lanthaum Carbonate Better for Phosphorus Absorption

Jody A. Charnow July 27, 2010

Mean net dietary phosphorus absorption is significantly lower after a single dose of lanthanum carbonate (LC) than after a single dose of sevelamer carbonate (SC), data suggest.
 

Phosphate Binder May Reduce the Number of Hospitalization Days

Jody A. Charnow April 17, 2010

Using sevelamer instead of calcium-based binders (CBBs) to treat hyperphosphatemia in dialysis patients can significantly decrease the number of days of hospitalization, shows a new analysis presented at the National Kidney Foundation's 2010 Spring Clinical Meetings. .
 

Sevelamer Carbonate May Impair Calcitriol Bioavailability

Jody A. Charnow April 17, 2010

Sevelamer carbonate significantly decreases the bioavailability of oral calcitriol when the two drugs are administered together, but lanthanum carbonate does not, show data presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.
 

Fluid Intake with Phosphate Binders Quantified

Jody A. Charnow April 17, 2010

The daily fluid intake with phosphate binder (PB) pills accounts for a significant portion of the daily fluid restriction in hemodialysis (HD) patients, suggest data presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.
 

High Phosphorus Linked to Lower Pulse Pressure in Women with CKD

Jody A. Charnow April 16, 2010

Higher serum phosphorus is associated with lower pulse pressure in women, but not men, with non-dialysis dependent CKD, according to researchers at the National Kidney Foundation's 2010 Spring Clinical Meetings.
 

Proton Pump Inhibitors May Improve Phosphate Control

Jody A. Charnow April 16, 2010

Proton pump inhibitors (PPIs) taken concurrently with phosphate binders may increase phosphate control in hemodialysis (HD) patients, according to researchers who presented their data at the National Kidney Foundation's 2010 Spring Clinical Meetings..
 

Lanthanum Carbonate Rapidly Reduces Phosphorus Levels

Jody A. Charnow April 16, 2010

Lanthanum carbonate rapidly reduces serum phosphorus levels in dialysis patients, according to an analysis of data from four clinical trials reported at the National Kidney Foundation's 2010 Spring Clinical Meetings.
 

Lanthanum Carbonate Provides Long-Term Phosphate Control

Jody A. Charnow April 15, 2010

Lanthanum carbonate provides sustained long-term reduction of serum phosphorus in dialysis patients, according to a study presented at the National Kidney Foundation 2010 Spring Clinical Meetings.
 

Findings Stress the Need for Phosphorus Counseling of CKD Patients

Jody A. Charnow April 15, 2010

The phosphorus content of a typical American diet significantly increases levels of fibroblast growth factor-23 (FGF-23), a pilot study suggests. The finding emphasizes the need to counsel CKD patients about limiting dietary phosphorus intake, according to researchers who presented the study at the National Kidney Foundation 2010 Spring Clinical Meetings.
 

Switching to Nocturnal Hemodialysis Beneficial

Jody A. Charnow April 15, 2010

It led to lower serum phosphorus levels, and fewer patients needed anti-hypertensive drugs.
 

Expert Series

Hyperphosphatemia in CKD - Part VI This article by Wajeh Y. Qunibi, MD, FACP of the University of Texas Health Sciences Center at San Antonio is the final in a series on managing hyperphosphatemia in CKD patients.
Hyperphosphatemia in CKD - Part V
This article by Neenoo Khosla, MD, and Stuart M. Sprague, DO, of the Northwestern University Feinberg School of Medicine in Chicago, is the fifth in a series on managing hyperphosphatemia in CKD patients.
Hyperphosphatemia in CKD - Part IV
This article by Michal L. Melamed, MD, MHS, of the Albert Einstein College of Medicine of Yeshiva University in Bronx, N.Y., is the fourth is a series on managing hyperphosphatemia in CKD patients.
Hyperphosphatemia in CKD - Part III
This article is the third in a series on hyperphosphatemia management in CKD patients. It is written by Kamyar Kalantar-Zadeh, MD, PhD, MPH, associate professor of medicine, pediatrics, and epidemiology at the David Geffen School of Medicine at the University of California-Los Angeles (UCLA) and director of Dialysis Expansion & Epidemiology in the Harbor-UCLA Division of Nephrology & Hypertension. He also is the Renal & Urology News medical director for nephrology.
Hyperphosphatemia in CKD - Part II
This article is the second in a series on hyperphosphatemia management in CKD patients. It is written by Joseph A. Coladonato, MD, MHS, medical director of South Greensboro Kidney Center, Carolina Kidney Associates, in Greensboro, N.C.
Hyperphosphatemia in CKD - Part I
Click here for the first article, which is by series editor Csaba P. Kovesdy, MD, chief of nephrology at the Salem VA Medical Center in Salem, Va. Dr. Kovesdy discusses whether the scientific evidence justifies the use of phosphate-lowering treatment.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions